$0.335
+0.008 (+2.29%)收盘时
ACTU 同业对比
In the context of the broader market, ACTU competes directly with industry leaders such as CNTX and QNRX. With a market capitalization of $8.03M, it holds a significant position in the sector. When comparing efficiency, ACTU's gross margin of N/A stands against CNTX's N/A and QNRX's N/A. Such benchmarking helps identify whether Actuate Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Actuate Therapeutics Inc 财务表现
Actuate Therapeutics has shown a consistent negative net income, with the latest reported net income of -5,625,749 USD for Q1 2026. The company's debt-to-equity ratio is high at 40.94%, indicating significant leverage.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
-17.80%
-4.91M
Operating Profit
FY2026Q2
YoY:
-18.20%
-4.87M
Net Income after Tax
FY2026Q2
YoY:
-33.33%
-0.20
EPS - Diluted
FY2026Q2
YoY:
+5.54%
-4.41M
Free Cash Flow
相关文章
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。